Oncothyreon provides the following update of its product development pipeline for 2008:
The Phase 3 pivotal trial of Stimuvax in patients with non-small cell lung cancer (NSCLC), START (Stimulating Targeted Antigenic Responses To NSCLC), continues enrollment in 2008. This year Oncothyreon expects to manufacture and to continue to provide to Merck KGaA substantial quantities of both Stimuvax and placebo to support START and potentially other additional trials of Stimuvax. In addition, Oncothyreon will continue the development of a large-scale process in preparation for the manufacture of commercial quantities of Stimuvax. Oncothyreon expects to receive an additional milestone payment related to Stimuvax during 2008.
START is a multi-center, randomized, double-blind, placebo-controlled study that will evaluate patients with documented unresectable stage IIIA or IIIB NSCLC who have had a response or stable disease after at least two cycles of platinum-based chemo-radiotherapy. The study is expected to involve more than 1,300 patients in approximately 30 countries.
Enrollment is ongoing in the Phase 1 dose escalation trial of PX-478 in patients with advanced metastatic cancer. Initial pharmacodynamic data from the early patients in this trial has been submitted for potential presentation at a scientific meeting at mid-year. More complete clinical data from this trial is expected in the second half of 2008.
PX-478 is a small molecule inhibitor of hypoxia inducible factor-1a
(HIF-1a), a component of a transcription factor that is an important
regulator of the tumor response to hypoxia. Pre-clinical data have
demonstrated that PX-478 can induce apoptosis, or programmed cell death, in
experimental tumor models, as well as the down-regulation of factors that
control angiogenesis, such as vascular endothelial growth factor (VEGF).
PX-478 is effective when delivered orally in animal models and
|SOURCE Oncothyreon Inc.|
Copyright©2008 PR Newswire.
All rights reserved